Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

The capacity of the recombinant Vaccinia virus GLV-1h68 as a single agent to efficiently treat different human or canine cancers has been shown in several preclinical studies. Currently, its human safety and efficacy are investigated in phase I/II clinical trials. In this study we set out to evaluat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine 2014-07, Vol.12 (1), p.197-197, Article 197
Hauptverfasser:	Hofmann, Elisabeth, Weibel, Stephanie, Szalay, Aladar A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - therapy Analysis Animals Antigens Antineoplastic Agents, Alkylating - therapeutic use Cancer therapies Cell culture Chemotherapy Clinical trials Complications and side effects Cyclophosphamide - therapeutic use Drug therapy Gene expression Grants Humans Infections Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - therapy Medical prognosis Mice Mice, Nude Oncolytic Virotherapy Patient outcomes Proteins Radiation therapy Risk factors Studies Tumors Vaccinia virus Viruses Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!